
Nov 19, 2026 · 8 min
Soitec surges as Novartis confronts patent pressure
Soitec Climbs, Babcock Rallies, Novartis Slips
The episode shows how guidance changes, defense-sector execution, and affordable EVs are reshaping investor attention across European and U.S. markets.
- 1Soitec raises its Photonics-SOI outlook as semiconductor and data-center strength lifts investor expectations.
- 2Babcock beats first-half expectations across revenue, margins, and earnings while expanding its manned and unmanned defense strategy.
- 3Novartis moderates medium-term sales guidance as generic competition intensifies concerns over its patent cliff.
Don't miss
Soitec’s latest Photonics-SOI guidance increase sends shares sharply higher amid semiconductor and data-center strength.
The brief
Soitec shares jump after another increase to its Photonics-SOI revenue outlook, benefiting from semiconductor and data-center strength ahead of Anthropic’s IPO.
Babcock rallies after beating first-half expectations on revenue, margins, and earnings, with investors backing its blend of manned and unmanned defense systems.
Novartis slips as it moderates medium-term sales-growth guidance through 2031; expected generic competition for a breast-cancer drug sharpens patent-cliff concerns.
The technology segment turns to Toyota and Subaru, whose relatively affordable SUVs helped more than double combined U.S. EV sales even as they remain minority players.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.